This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma

This study has been completed.
Information provided by (Responsible Party):
Tamotsu Ishizuka, Gunma University Identifier:
First received: April 24, 2009
Last updated: February 3, 2013
Last verified: February 2013
Extracorporeal leukocytapheresis (LCAP) or granulocytapheresis (GCAP) has been used in the treatment of patients with rheumatoid arthritis and ulcerative colitis and has shown promising safety and efficacy. LCAP and GCAP seem to be effective for steroid-resistant inflammation. The investigators have already reported safety and efficacy of GCAP in refractory asthma and expect the beneficial effect of LCAP in refractory asthma. In this study, in order to improve the therapeutic effect of LCAP by increasing the quantity of leukocytes that were removed, the investigators conducted a clinical study to investigate safety and efficacy of high-dose LCAP performed using a larger filter and an increased dose of the blood volume per body weight treated, as an possible therapy for refractory asthma.

Condition Intervention
Bronchial Asthma Procedure: Leukocytapheresis

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Patients With Refractory Asthma

Further study details as provided by Tamotsu Ishizuka, Gunma University:

Primary Outcome Measures:
  • Improvement of morning peak flow rate (PEFR) or evening PEFR [ Time Frame: 4 weeks after the treatment ]

Secondary Outcome Measures:
  • An improved score of asthma control test [ Time Frame: 4 weeks after the treatment ]

Enrollment: 6
Study Start Date: November 2008
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Procedure: Leukocytapheresis
5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients fulfilled the 2001 criteria for refractory asthma in American Thoracic Society.

Exclusion Criteria:

  • Pregnant women.
  • Patients with severe cardiovascular diseases.
  • Patients with infective diseases.
  • Patients with leukocytopenia or anemia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00888472

Department Medicine and Molecular Science, Gunma University Graduate School of Medicine
Maebashi, Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
Principal Investigator: Tamotsu Ishizuka, M.D. Assistant Professor
  More Information

Responsible Party: Tamotsu Ishizuka, Clinical Professor, Gunma University Identifier: NCT00888472     History of Changes
Study First Received: April 24, 2009
Last Updated: February 3, 2013

Keywords provided by Tamotsu Ishizuka, Gunma University:
Extracorporeal leukocytapheresis

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on August 16, 2017